ArticleCancer prevention research (Philadelphia, Pa.)2009
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
Article in Cancer prevention research (Philadelphia, Pa.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Activity-dependent COX-2 proteolysis modulates aerobic respiration and proliferation in a prostaglandin-independent manner.iScience · 2024Article
- Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment:Veterinary world · 2024Review
- Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats.Cancers · 2023Article
- Cyclooxygenase-2 induces neoplastic transformation by inhibiting p53-dependent oncogene-induced senescence.Scientific reports · 2021Article
- Animal Models of Colorectal Cancer: From Spontaneous to Genetically Engineered Models and Their Applications.Veterinary sciences · 2021Review
- Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Review
- Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth.Carcinogenesis · 2015Article
- Simultaneous presentation of pancreatic cancer in a genetically unrelated couple.BMJ case reports · 2015Article
- Id Proteins Contribute to Tumor Development and Metastatic Colonization in a Model of Bladder Carcinogenesis.Bladder cancer (Amsterdam, Netherlands) · 2015Article
- Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention.The Journal of investigative dermatology · 2014Review
- Current animal models of bladder cancer: Awareness of translatability (Review).Experimental and therapeutic medicine · 2014Article
- Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2014Article
- NSAIDs inhibit tumorigenesis, but how?Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Review
- Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study.Urologic oncology · 2013Article
- Obesity, metabolism and the microenvironment: Links to cancer.Journal of carcinogenesis · 2013Review
- The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Nonsteroidal anti-inflammatory drugs (NSAID) have been highly effective in preventing colon, urinary bladder, and skin cancer preclinically, and also in clinical trials of colon adenoma formation. However, certain NSAIDs cause gastrointestinal ulceration and may increase cardiovascular events. Naproxen seems to cause the lowest cardiovascular events of the common NSAIDs other than aspirin. Nitric oxide (NO)-naproxen was tested based on the finding that adding a NO group to NSAIDs may help alleviate GI toxicity. In the azoxymethane-induced rat colon aberrant crypt foci (ACF) model, naproxen administered at 200 and 400 ppm in the diet reduced mean ACFs in the colon by about 45% to 60%, respectively. NO-naproxen was likewise administered in the diet at roughly equimolar doses (300 and 600 ppm) and reduced total ACF by 20% to 40%, respectively. In the hydroxybutyl (butyl) nitrosamine rat urinary bladder cancer model, NO-naproxen was given at 183 or 550 ppm in the diet, and naproxen at 128 ppm. The NO-naproxen groups had 77% and 73% decreases, respectively, in the development of large urinary bladder tumors, whereas the 128 ppm naproxen group also showed a strong decrease (69%). If treatments were started 3 months after hydroxybutyl (butyl) nitrosamine, NO-naproxen (550 ppm) and naproxen (400 ppm) were also highly effective (86-94% decreases). In the methylnitrosourea-induced mammary cancer model in rats, NO-naproxen and naproxen showed nonsignificant inhibitions (12% and 24%) at 550 and 400 ppm, respectively. These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.